Categories
Tags
Abbott Advertising AstraZeneca Barack Obama Biotechnology and Pharmaceuticals Breast cancer Bristol Myers Squibb business Cancer Clinical trial Conditions and Diseases Deal Eli Lilly European Commission European Union FDA Food and Drug Administration Genentech generics GlaxoSmithKline Google GSK HBA Health Health care Johnson & Johnson layoffs Lilly Margaret Hamburg Marketing Merck Novartis Pfizer Pharma Pharmaceutical drug pharmaceutical industry Research and development Roche Sanofi-Aventis Schering Plough social media Twitter U.S. Food and Drug Administration United States Wyeth
Technology News
BioPharm News- Shire Gains European Approval for its Gaucher Disease Treatment
- Mtech Bioprocess Scale-Up Facility to Double in Staff and Size
- ImClone Closes Plant in New Jersey, Consolidating Erbitux Manufacture
- EMA and FDA Seek Applicants for Joint GMP Inspections
- ATMI Expands Bloomington, Minnesota Manufacturing Facility
Clinical Trials News- CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems
- ACR Image Metrix Establishes Global Presence
- BioPharm Systems Named to the 2010 Inc. 500|5000 List of Fastest-Growing Companies in the U.S.
- CRF Health Doubles North American Headquarters
- Oracle Completes Acquisition of Phase Forward
Blogroll
-
Meta
Tag Archives: DDMAC
Building a Better Brief Summary
Image via Wikipedia
FDA wanted to find out what people really think of the risk information printed on the back of pharmaceutical advertising. Surprise, people tend to absorb far less information from the giant blocks of text printed in drab language.
DDMAC social science analyst Amy O’Donoghue explained FDA’s recent study results to an audience of marketers [...]
Posted in Advertising, Regulatory Also tagged Advertising, Brief Summary, DIA, FDA, Marketing 4 Comments
Live from DIA: FDA Warning Letters Stir More Questions Than Answers
A panel of regulators from FDA’s Division of Drug Marketing, Advertising, and Communications were taken to task, this morning at the Drug Information Association’s annual meeting, for 14 warning letters levied on drug companies for not including risk information in online search ads.
A Sanofi Aventis employee complained about the 14 warning letters and asked why [...]
Posted in Advertising, Regulatory Also tagged DIA, FDA, Marketing, new media, Search, Warning Letters 1 Comment
The Regulation Wars
Last Friday, FDA’s Division of Drug Marketing, Advertising, and Communications (DDMAC) issued 14 untitled letters to pharma companies as a result of online advertisements that appeared as sponsored links on search engine results pages. There were already plenty of guidelines on marketing to consumers being enforced by PhRMA, but now comes a crackdown on Internet [...]
Is FDA Watching YouTube?
Two weeks ago, Shire received a warning letter for posting a sponsored testimonial on YouTube without including risk information. Shire was very open when I called them up and admitted that the video was posted by accident and immediately removed when it was brought to the company’s attention.
While I’m not 100 percent positive, it [...]
Posted in E-Media, Marketing, Regulatory Also tagged Advertising, DTC, emedia, FDA, Shire, Viagra, Warning Letter, YouTube 3 Comments

New FDA Campaign Targets Detailing, Trade Shows